Composition and method for treating neurological disease

  • US 8,889,740 B1
  • Filed: 08/04/2014
  • Issued: 11/18/2014
  • Est. Priority Date: 11/24/2004
  • Status: Active Grant
First Claim
Patent Images

1. A dosage form suitable for once-daily administration to a human subject consisting of (i) 50 mg to 500 mg of a drug selected from the group consisting of amantadine and pharmaceutically acceptable salts thereof, and (ii) at least one excipient, wherein at least 50% of the drug in the dosage form is in an extended release form, and wherein the dosage form provides a mean change in amantadine plasma concentration as a function of time (dC/dT) as measured in a single dose human pharmacokinetic study over the time period between 2 hours and 4 hours after administration that is less than 30% of the dC/dT provided by the same quantity of the drug in an immediate release form as measured in a single dose human pharmacokinetic study over the time period between 0 and 2 hours after administration.

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×